Skip to main content
KYMR
NASDAQ Life Sciences

Atlas Venture Fund X Files Intent to Sell $48 Million in Kymera Therapeutics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$115.91
Mkt Cap
$9.58B
52W Low
$36.65
52W High
$130.05
52W Position info
216% above low
Off High info
11% below high
Rel. Volume info
5.7× avg
Market data snapshot near publication time

KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (5.7× avg).

Summary

A major institutional shareholder, Atlas Venture Fund X, has filed to sell $48 million in Kymera Therapeutics stock, continuing a trend of significant insider distribution.


Key Events · Ownership and Investor Activity · KYMR

  • Significant Proposed Sale

    Atlas Venture Fund X, LP, a major institutional shareholder, has filed a Form 144 indicating its intent to sell 480,992 shares of common stock, valued at approximately $48.04 million.

  • Ongoing Shareholder Distribution

    This proposed sale adds to approximately $63.67 million in shares already sold by Atlas Venture entities and other filers over the past three months, signaling continued liquidation by large shareholders.


Analysis · KYMR · Life Sciences

Atlas Venture Fund X, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $48 million worth of Kymera Therapeutics common stock. This proposed sale represents a notable liquidation by a major investor and follows a pattern of distribution by Atlas Venture entities and other insiders, totaling over $63 million in sales over the past three months. This continued selling pressure from a large shareholder could create an overhang on the stock.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KYMR was trading at $115.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KYMR - Latest Insights

KYMR
Oct 29, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $122.01
Real-time Price: $131.07 info
Change: +$9.06 (+7%) info
Market Cap: $11.246B info
KYMR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $122.01
Real-time Price: $131.07 info
Change: +$9.06 (+7%) info
Market Cap: $11.246B info
KYMR
Aug 06, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $105.48
Real-time Price: $131.07 info
Change: +$25.59 (+24%) info
Market Cap: $11.246B info
KYMR
Aug 05, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $104.52
Real-time Price: $131.07 info
Change: +$26.55 (+25%) info
Market Cap: $11.246B info
KYMR
Aug 05, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $104.52
Real-time Price: $131.07 info
Change: +$26.55 (+25%) info
Market Cap: $11.246B info